{"Q": 1, "answer": "no", "rationale": "'very quickly' contains an intensifier but modifies 'quickly', not a risk adjective.", "method": "llm_batch", "batch_id": "batch_1_13428", "batch_size": 200, "batch_pos": 69, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment describes plans and potential response speed (Q5 Preparedness).", "method": "llm_batch", "batch_id": "batch_2_15640", "batch_size": 200, "batch_pos": 59, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment does not contain a moderate verb from the approved list paired with scale/impact. 'could respond' is hypothetical.", "method": "llm_batch", "batch_id": "batch_3_17892", "batch_size": 200, "batch_pos": 46, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "No loaded rhetorical question present.", "method": "llm_batch", "batch_id": "batch_4_15152", "batch_size": 200, "batch_pos": 43, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "Reports plans and capability neutrally.", "method": "llm_batch", "batch_id": "batch_5_16228", "batch_size": 200, "batch_pos": 43, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "The segment contains 'small human trial' but 'small' is not a Q6 minimiser token.", "method": "llm_batch", "batch_id": "batch_6_20244", "batch_size": 200, "batch_pos": 26, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"hop_idx": 7, "answer": "uncertain", "rationale": "Missing response from batch", "method": "fallback", "batch_id": "batch_7_16056", "batch_size": 200, "batch_pos": 20, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "Segment does not contain a bare negation.", "method": "llm_batch_retry", "retry": 1, "batch_id": "batch_7_16056_r1", "batch_size": 200, "batch_pos": 20, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "Describes plans to 'launch a small human trial' and ability to 'respond very quickly' (capability/preparedness) without explicit calming keywords.", "method": "llm_batch", "batch_id": "batch_8_10324", "batch_size": 200, "batch_pos": 148, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
